[
  {
    "ts": "2026-02-11T08:30:00+00:00",
    "headline": "[Latest] Global Cell Therapy Raw Materials Market Size/Share Worth USD 29.3 Billion by 2035 at a 18.9% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)",
    "summary": "[220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global Cell Therapy Raw Materials Market size & share revenue was valued at approximately USD 5.2 Billion in 2025 and is expected to reach USD 6.1 Billion in 2026 and is expected to reach around USD 29.3 Billion by 2035, at a CAGR of 18.9% between 2026 and 2035. The key market players listed in the report with their sales, revenues and strategies are Thermo Fisher Scientifi",
    "url": "https://finance.yahoo.com/news/latest-global-cell-therapy-raw-083000732.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "2d9d4e5a-57d6-3ebf-9253-c5ff525668f4",
      "content": {
        "id": "2d9d4e5a-57d6-3ebf-9253-c5ff525668f4",
        "contentType": "STORY",
        "title": "[Latest] Global Cell Therapy Raw Materials Market Size/Share Worth USD 29.3 Billion by 2035 at a 18.9% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)",
        "description": "",
        "summary": "[220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global Cell Therapy Raw Materials Market size & share revenue was valued at approximately USD 5.2 Billion in 2025 and is expected to reach USD 6.1 Billion in 2026 and is expected to reach around USD 29.3 Billion by 2035, at a CAGR of 18.9% between 2026 and 2035. The key market players listed in the report with their sales, revenues and strategies are Thermo Fisher Scientifi",
        "pubDate": "2026-02-11T08:30:00Z",
        "displayTime": "2026-02-11T08:30:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/0bec09301614ea6a3ee415db83086891",
          "originalWidth": 2514,
          "originalHeight": 1281,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/2CrZC42kgw2SjdY2CY6ucw--~B/aD0xMjgxO3c9MjUxNDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/0bec09301614ea6a3ee415db83086891.cf.webp",
              "width": 2514,
              "height": 1281,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/91DUI4_rVm8Et9pJYV6I4Q--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/0bec09301614ea6a3ee415db83086891.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/latest-global-cell-therapy-raw-083000732.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/latest-global-cell-therapy-raw-083000732.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "CRL"
            },
            {
              "symbol": "JNJ"
            },
            {
              "symbol": "TMO"
            },
            {
              "symbol": "MKGAF"
            },
            {
              "symbol": "DHR"
            },
            {
              "symbol": "SDMHF"
            },
            {
              "symbol": "GRFS"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-11T04:34:45+00:00",
    "headline": "1 S&P 500 Stock with Competitive Advantages and 2 We Ignore",
    "summary": "The S&P 500 (^GSPC) is home to the biggest and most well-known companies in the market, making it a go-to index for investors seeking stability. But not all large-cap stocks are created equal - some are struggling with slowing growth, declining margins, or increased competition.",
    "url": "https://finance.yahoo.com/news/1-p-500-stock-competitive-043445743.html",
    "source": "StockStory",
    "provider": "yfinance",
    "raw": {
      "id": "7f42d009-2aaa-3f58-ae6a-d9f08cec8418",
      "content": {
        "id": "7f42d009-2aaa-3f58-ae6a-d9f08cec8418",
        "contentType": "STORY",
        "title": "1 S&P 500 Stock with Competitive Advantages and 2 We Ignore",
        "description": "",
        "summary": "The S&P 500 (^GSPC) is home to the biggest and most well-known companies in the market, making it a go-to index for investors seeking stability. But not all large-cap stocks are created equal - some are struggling with slowing growth, declining margins, or increased competition.",
        "pubDate": "2026-02-11T04:34:45Z",
        "displayTime": "2026-02-11T04:34:45Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/stockstory_922/7509c571642c6ae9d1577bc3c4457c17",
          "originalWidth": 1400,
          "originalHeight": 700,
          "caption": "CRL Cover Image",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/PLZRbui545u2bOcqTkunEw--~B/aD03MDA7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/stockstory_922/7509c571642c6ae9d1577bc3c4457c17.cf.webp",
              "width": 1400,
              "height": 700,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/YlRDliezLyxJ3r.biO59fw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/stockstory_922/7509c571642c6ae9d1577bc3c4457c17.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "StockStory",
          "url": "https://stockstory.org/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/1-p-500-stock-competitive-043445743.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/1-p-500-stock-competitive-043445743.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "^GSPC"
            },
            {
              "symbol": "ACN"
            },
            {
              "symbol": "FITB"
            },
            {
              "symbol": "FITBM"
            },
            {
              "symbol": "FITBP"
            },
            {
              "symbol": "CRL"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-11T15:00:11+00:00",
    "headline": "Analysts Estimate Charles River Laboratories (CRL) to Report a Decline in Earnings: What to Look Out for",
    "summary": "Charles River (CRL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.",
    "url": "https://finance.yahoo.com/news/analysts-estimate-charles-river-laboratories-150011657.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "de737f00-6412-3c4b-a910-a82a410f73bd",
      "content": {
        "id": "de737f00-6412-3c4b-a910-a82a410f73bd",
        "contentType": "STORY",
        "title": "Analysts Estimate Charles River Laboratories (CRL) to Report a Decline in Earnings: What to Look Out for",
        "description": "",
        "summary": "Charles River (CRL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.",
        "pubDate": "2026-02-11T15:00:11Z",
        "displayTime": "2026-02-11T15:00:11Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/8442d24e11d454aa89061259a9714d43",
          "originalWidth": 900,
          "originalHeight": 601,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/E8QyPjKtRaOQj91uVCJHQA--~B/aD02MDE7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/8442d24e11d454aa89061259a9714d43.cf.webp",
              "width": 900,
              "height": 601,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/hjTg63kWHBfUb8JQmmr1kg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/8442d24e11d454aa89061259a9714d43.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/analysts-estimate-charles-river-laboratories-150011657.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/analysts-estimate-charles-river-laboratories-150011657.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "CRL"
            },
            {
              "symbol": "LH"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]